import streamlit as st

import google.generativeai as genai



# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªèˆ‡å¯¦è­‰åœ–æ›¸é¤¨ (2026 æœ€çµ‚å…¨åŠŸèƒ½æ•´åˆç‰ˆ) ---

st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")



st.markdown("""

    <style>

    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');

    

    /* === æ¥µè‡´ç·Šç·»åŒ– UI èˆ‡ é«˜å°æ¯”åº¦æ–‡å­— === */

    html, body, [class*="css"] {

        font-family: 'Noto Sans TC', 'Roboto', sans-serif;

        background-color: #F4F7F9;

        color: #1A1A1A;

        font-size: 19px !important;

        line-height: 1.1;

    }



    .main-title {

        font-size: 32px !important; font-weight: 900; color: #004D40;

        padding: 5px 0; border-bottom: 3px solid #4DB6AC; margin-bottom: 5px;

    }



    /* å¤§éšæ®µæ–¹å¡Šï¼šé›¶ç•™ç™½è¨­è¨ˆ */

    .big-stage-card {

        border-radius: 10px; padding: 0px; 

        box-shadow: 0 2px 10px rgba(0,0,0,0.08);

        border: 2px solid transparent; background: white; 

        margin-bottom: 4px; overflow: hidden; height: auto !important;

    }

    .big-stage-header {

        font-size: 17px !important; font-weight: 900; color: white;

        padding: 5px; text-align: center;

    }



    /* å­å€å¡Š (SoC èˆ‡åˆ†å­äºå‹) */

    .sub-block {

        margin: 2px 4px; padding: 4px;

        border-radius: 6px; background: #F8F9FA;

        border-left: 5px solid #546E7A;

    }

    .sub-block-title {

        font-size: 13px; font-weight: 900; color: #37474F;

        margin-bottom: 1px; border-bottom: 1.1px solid #CFD8DC; padding-bottom: 1px;

    }

    .sub-block-content {

        font-size: 14px; color: #263238; font-weight: 500; line-height: 1.15;

    }



    /* éšæ®µé…è‰² */

    .card-p-tx { border-color: #2E7D32; }

    .header-p-tx { background: linear-gradient(135deg, #43A047, #2E7D32); }

    .card-p-mt { border-color: #1565C0; }

    .header-p-mt { background: linear-gradient(135deg, #1E88E5, #1565C0); }

    .card-r-tx { border-color: #E65100; }

    .header-r-tx { background: linear-gradient(135deg, #FB8C00, #E65100); }

    .card-r-mt { border-color: #6A1B9A; }

    .header-r-mt { background: linear-gradient(135deg, #8E24AA, #6A1B9A); }



    /* æŒ‰éˆ•æ¨£å¼ï¼šæ·±é»‘è‰²åŠ ç²— (#1A1A1A) */

    .stPopover button { 

        font-weight: 900 !important; font-size: 11px !important; 

        border-radius: 4px !important; margin-top: 1px !important;

        padding: 1px 6px !important; width: 100% !important; 

        text-align: left !important; color: #1A1A1A !important; 

        border: 1px solid rgba(0,0,0,0.15) !important;

        box-shadow: 0 1px 3px rgba(0,0,0,0.1) !important;

    }

    

    .stPopover button[aria-label*="ğŸ“š"] { background: #ECEFF1 !important; border-left: 5px solid #455A64 !important; }

    .stPopover button[aria-label*="Eli Lilly"] { background: #FCE4EC !important; border-left: 5px solid #E91E63 !important; } 

    .stPopover button[aria-label*="Daiichi Sankyo"] { background: #E8F5E9 !important; border-left: 5px solid #4CAF50 !important; } 

    .stPopover button[aria-label*="MSD"] { background: #E3F2FD !important; border-left: 5px solid #1976D2 !important; } 

    .stPopover button[aria-label*="AstraZeneca"] { background: #F3E5F5 !important; border-left: 5px solid #8E24AA !important; } 

    .stPopover button[aria-label*="GSK"] { background: #FFF3E0 !important; border-left: 5px solid #F57C00 !important; } 

    .stPopover button[aria-label*="Gilead"] { background: #E1F5FE !important; border-left: 5px solid #03A9F4 !important; } 

    .stPopover button[aria-label*="Seagen"] { background: #EEEEEE !important; border-left: 5px solid #212121 !important; } 



    .detail-section { background: white; border-radius: 18px; padding: 25px; border: 1px solid #CFD8DC; box-shadow: 0 10px 40px rgba(0,0,0,0.05); }

    .hr-big-val { font-family: 'Roboto', sans-serif; font-size: 45px !important; font-weight: 900; color: #D84315; }

    </style>

    """, unsafe_allow_html=True)



# --- 1. æŒ‡å¼•å°èˆªæ•¸æ“šåº«ï¼šåŒ…å« MOC é‘‘åˆ¥èˆ‡ PSOC/PROC åˆ†æµ ---

guidelines_nested = {

    "Endometrial": [

        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [

            {"title": "MMRd / MSI-H / dMMR", "content": "ä¸€ç·šæ¨™ç«¿ï¼šChemo + PD-1 (GY018/RUBY)ã€‚Dostarlimab ç²ç›Šæ¥µé¡¯è‘—ã€‚"},

            {"title": "NSMP / pMMR / MSS", "content": "æ’é™¤åˆ†å‹ã€‚è¦– ER/Grade æ¬Šé‡æ±ºç­–ï¼›äºŒç·šè€ƒæ…® Pembro+Lenvaã€‚"},

            {"title": "POLEmut / p53abn", "content": "POLE: æœ€ä½³é å¾Œï¼›p53abn: æœ€å·®é å¾Œï¼Œéœ€ç©æ¥µè¼”åŠ©æ²»ç™‚ã€‚"}]},

        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "IO Maintenance", "content": "ä¸€ç·š IO æ²»ç™‚å¾Œæ¥çºŒç¶­æŒç›´åˆ°ç–¾ç—…é€²å±• (PD)ã€‚"}]},

        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "Recurrent EC", "content": "äºŒç·šæ–¹æ¡ˆï¼šæ¨™é¶+å…ç–« (pMMR) æˆ– IO å–®è—¥ (MMRd/GARNET)ã€‚"}]},

        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒæœ‰æ•ˆæ²»ç™‚ç›´åˆ°ä¸å¯è€å—æˆ–é€²å±•ã€‚"}]}

    ],

    "Ovarian": [

        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [

            {"title": "HGSC / Endometrioid", "content": "æ‰‹è¡“ (PDS/IDS) + Carboplatin/Paclitaxel Â± Bevacizumabã€‚"},

            {"title": "Mucinous (MOC) é‘‘åˆ¥", "content": "åˆ¤å®šï¼šCK7+/SATB2- (åŸç™¼)ã€‚1. Expansile: é å¾Œä½³ã€‚ 2. Infiltrative: é«˜å¾©ç™¼é¢¨éšªï¼Œå»ºè­°ç©æ¥µåŒ–ç™‚ã€‚"}]},

        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [

            {"title": "BRCA mutated", "content": "Olaparib å–®è—¥ç¶­æŒ 2å¹´ã€‚"}, {"title": "HRD positive (wt)", "content": "Olaparib+Bev (2å¹´) æˆ– Niraparib å–®è—¥ (3å¹´)ã€‚"}]},

        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (R-TX)", "css": "r-tx", "subs": [

            {"title": "PSOC (Sensitive)", "content": "PFI > 6mã€‚å«é‰‘é›™è—¥åŒ–ç™‚ Â± Bevã€‚è©•ä¼°äºŒæ¬¡æ‰‹è¡“ (DESKTOP)ã€‚"},

            {"title": "PROC (Resistant)", "content": "PFI < 6mã€‚å–®è—¥åŒ–ç™‚ Â± Bev æˆ–æ¨™é¶ ADC (MIRASOL/FRAmework)ã€‚"}]},

        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Platinum Sensitive Maint", "content": "æ•‘æ´ç·©è§£å¾ŒçºŒä»¥ PARPi ç¶­æŒæ²»ç™‚ã€‚"}]}

    ],

    "Cervical": [

        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [

            {"title": "CCRT (Locally Advanced)", "content": "åŒæ­¥åŒ–æ”¾ç™‚ã€‚é«˜é¢¨éšªè€…åŒæ­¥ IO (A18) æˆ–èª˜å°åŒ–ç™‚ (INTERLACE)ã€‚"},

            {"title": "Early Stage (Surgery)", "content": "æ ¹æ²»æ€§é–‹è…¹è¡“ (LACC)ã€‚ä½é¢¨éšªè€…é¸å–®ç´”åˆ‡é™¤ (SHAPE)ã€‚"}]},

        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Metastatic Maint", "content": "1L è½‰ç§»æ€§ IO æ–¹æ¡ˆå¾Œå»¶çºŒç¶­æŒè‡³é€²å±•ã€‚"}]},

        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [

            {"title": "Recurrent / Metastatic", "content": "ä¸€ç·š Pembro + åŒ–ç™‚ Â± Bevã€‚äºŒç·š ADC (Tivdak) æˆ– IO (EMPOWER)ã€‚"}]},

        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒæœ‰æ•ˆæ²»ç™‚ç›´è‡³é€²å±•ã€‚"}]}

    ]

}



# --- 2. å¯¦è­‰é‡Œç¨‹ç¢‘ (ğŸ“š Milestone Library - å®Œæ•´ 24 é …æ·±åº¦å°æ‡‰) ---

milestone_db = [

    # Endometrial

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["MMRd / MSI-H / dMMR"], "name": "ğŸ“š RUBY", "drug": "Dostarlimab + CP", "summary": "FIGO III-IV/Recurrentã€‚dMMR æ­»äº¡é¢¨éšªé™ 68% (HR 0.32)ï¼›å…¨äººç¾¤ mOS 44.6m vs 28.2m (HR 0.69)ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["MMRd / MSI-H / dMMR", "NSMP / pMMR / MSS"], "name": "ğŸ“š NRG-GY018", "drug": "Pembrolizumab + CP", "summary": "FIGO III-IV/Recurrentã€‚dMMR PFS HR 0.30ï¼›pMMR äº¦é¡¯è‘—æ”¹å–„ (HR 0.54)ã€‚æ”¯æŒä¸€ç·šä¸è«– MMR ä¹‹ IO ç²ç›Šã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["NSMP / pMMR / MSS"], "name": "ğŸ“š DUO-E", "drug": "Durvalumab Â± Olaparib", "summary": "ä¸€ç·šæ™šæœŸã€‚ä¸‰è—¥çµ„ PFS HR 0.57 (vs CP)ï¼›Durva çµ„ HR 0.77ã€‚å»ºç«‹å…ç–«ç¶­æŒç­–ç•¥ã€‚"},

    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["MMRd / MSI-H / dMMR"], "name": "ğŸ“š AtTEnd", "drug": "Atezolizumab + CP", "summary": "ä¸€ç·šæ™šæœŸã€‚dMMR PFS HR 0.36ï¼Œç²ç›Šæ¥µå¤§ï¼›å…¨é«” OS HR 0.82ã€‚æ”¯æŒ PD-(L)1 ä½µåŒ–ç™‚è­‰æ“šéˆã€‚"},

    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š KEYNOTE-775", "drug": "Lenvatinib + Pembro", "summary": "äºŒç·š(æ›¾å«é‰‘)ã€‚pMMR OS 17.4m vs 12.0m (HR 0.68)ï¼›5å¹´ OS 16.7% vs 7.3%ã€‚MSS äºŒç·šæ¨™æº–ã€‚"},



    # Cervical

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["CCRT (Locally Advanced)"], "name": "ğŸ“š KEYNOTE-A18", "drug": "Pembrolizumab + CCRT", "summary": "é«˜é¢¨éšª LACCã€‚36å€‹æœˆ OS 82.6% vs 74.8% (HR 0.67)ã€‚ç¢ºç«‹åŒæ­¥å…ç–«æ¨™æº–ã€‚"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["CCRT (Locally Advanced)"], "name": "ğŸ“š INTERLACE", "drug": "Induction Carbo/Pacli", "summary": "å±€éƒ¨æ™šæœŸã€‚6é€±èª˜å°åŒ–ç™‚å¾Œæ¥ CCRTï¼Œ5å¹´ OS 80% vs 72% (HR 0.60)ã€‚ç¾æˆåŒ–ç™‚å¯æå‡ç”Ÿå­˜ã€‚"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["CCRT (Locally Advanced)"], "name": "ğŸ“š CALLA (é™°æ€§)", "drug": "Durvalumab + CCRT", "summary": "å±€éƒ¨æ™šæœŸã€‚æ•´é«”æœªé”çµ±è¨ˆå­¸ PFS æ”¹å–„ã€‚HR 0.84ã€‚æç¤ºéœ€æ›´ç²¾æº–åˆ†æµã€‚"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurrent / Metastatic"], "name": "ğŸ“š KEYNOTE-826", "drug": "Pembro + Chemo Â± Bev", "summary": "R/M ä¸€ç·šã€‚å…¨äººç¾¤ OS HR 0.63ï¼›CPSâ‰¥1 HR 0.60ã€‚å¥ å®š R/M ä¸€ç·š IO åŸºç¤ã€‚"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurrent / Metastatic"], "name": "ğŸ“š BEATcc", "drug": "Atezolizumab + Chemo+Bev", "summary": "R/M ä¸€ç·šã€‚PFS HR 0.62ï¼ŒOS HR 0.68ã€‚æä¾›ä¸€ç·šå…ç–«ä½µç”¨æ–°é¸é …ã€‚"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurrent / Metastatic"], "name": "ğŸ“š EMPOWER-Cx 1", "drug": "Cemiplimab", "summary": "äºŒç·šã€‚OS 12.0m vs 8.5m (HR 0.69)ï¼›ç²ç›Šä¸ä¾è³´ PD-L1 è¡¨ç¾ã€‚å¾Œç·š IO å–®è—¥è­‰æ“šã€‚"},

    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["Recurrent / Metastatic"], "name": "ğŸ“š innovaTV 301", "drug": "Tisotumab Vedotin", "summary": "äºŒ/ä¸‰ç·šã€‚OS 11.5m vs 9.5m (HR 0.70)ï¼ŒORR 17.8%ã€‚ADC é€²å…¥æ¨™æº–å¾Œç·šã€‚"},

    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Early Stage (Surgery)"], "name": "ğŸ“š SHAPE trial", "drug": "Simple Hysterectomy", "summary": "æ—©æœŸä½é¢¨éšª(<2cm)ã€‚3å¹´å¾©ç™¼ç‡ 2.5% (SH) vs 2.2% (RH)ã€‚æ”¯æŒæ‰‹è¡“é™éšã€‚"},



    # Ovarian

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutated"], "name": "ğŸ“š SOLO-1", "drug": "Olaparib", "summary": "ä¸€ç·šç¶­æŒã€‚7å¹´ survival 67% (vs 46.5%, HR 0.33)ã€‚ç¢ºç«‹æ²»ç™’æ½›åŠ›é‡Œç¨‹ç¢‘ã€‚"},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive (wt)"], "name": "ğŸ“š PAOLA-1", "drug": "Olaparib + Bevacizumab", "summary": "ä¸€ç·šç¶­æŒã€‚HRD+ æ—ç¾¤ 5å¹´ OS é¡¯è‘—æ”¹å–„ (HR 0.62)ã€‚ç¢ºç«‹ã€ŒPARPi + anti-VEGFã€è·¯å¾‘ã€‚"},

    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive (wt)", "HRD negative / pHRD"], "name": "ğŸ“š ATHENAâ€“MONO", "drug": "Rucaparib", "summary": "ä¸€ç·šç¶­æŒã€‚ITT PFS HR 0.52 (28.7m vs 11.3m)ï¼›æ”¯æŒå»£æ³› PARPi æ‡‰ç”¨ã€‚"},

    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], "name": "ğŸ“š NOVA", "drug": "Niraparib", "summary": "å¾©ç™¼ç¶­æŒã€‚gBRCA HR 0.27ï¼›é gBRCA HR 0.45ã€‚é¡¯è‘—å»¶ç·©å¾©ç™¼ã€‚"},

    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], "name": "ğŸ“š ARIEL3", "drug": "Rucaparib", "summary": "å¾©ç™¼ç¶­æŒã€‚Rucaparib åœ¨æ‰€æœ‰åˆ†å±¤(BRCA/HRD+/ITT)å‡ PFS æ”¹å–„ã€‚"},

    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], "name": "ğŸ“š SOLO2",
